Dr. Hayes Discusses Anti-Estrogen Therapy Beyond 5 Years in Breast Cancer

Daniel F. Hayes, MD
Published: Wednesday, May 31, 2017



Daniel F. Hayes, MD, professor of University of Michigan Comprehensive Cancer Center, discusses anti-estrogen therapy beyond 5 years in breast cancer.

One of the big questions facing the breast cancer field, Hayes says, is what to do about women who have made it to 5 years on an anti-estrogen therapy.

There are now 4 trials to suggest that continued anti-estrogen therapy beyond 5 years suppresses late recurrence.
 


Daniel F. Hayes, MD, professor of University of Michigan Comprehensive Cancer Center, discusses anti-estrogen therapy beyond 5 years in breast cancer.

One of the big questions facing the breast cancer field, Hayes says, is what to do about women who have made it to 5 years on an anti-estrogen therapy.

There are now 4 trials to suggest that continued anti-estrogen therapy beyond 5 years suppresses late recurrence.
 

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Cancer Summaries and Commentaries™: Update from Chicago: Advances in the Treatment of Breast CancerJul 31, 20181.0
Community Practice Connections™: Medical Crossfire®: Translating Lessons Learned with PARP Inhibition to the Treatment of Breast Cancer—Expert Exchanges on Novel Strategies to Personalize CareAug 29, 20181.5
Publication Bottom Border
Border Publication
x